An announcement from Icecure Medical ( (ICCM) ) is now available.
On March 17, 2025, IceCure Medical announced that it received a Notice of Allowance in China for its novel cryogenic pump, part of its next-generation cryoablation technology. This development marks a significant expansion of IceCure’s intellectual property portfolio, complementing existing patents in the U.S., Europe, and Japan. The new cryogenic pump, which operates in a closed circuit and is submersible in liquid nitrogen, enhances IceCure’s cryoablation systems by improving temperature control and cooling rates, thus supporting longer procedures without the need for refilling. This advancement reinforces IceCure’s position as a leader in LN2-based cryoablation technology, potentially impacting its market reach and stakeholder interests by broadening clinical applications and increasing commercial traction.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, is a company specializing in the development and marketing of advanced cryoablation therapy systems that utilize liquid nitrogen to destroy tumors by freezing. Their primary focus areas include breast, kidney, bone, and lung cancer. The company’s flagship product, the ProSense® system, offers a minimally invasive alternative to surgical tumor removal and is marketed globally, with approvals in the U.S., Europe, and China.
YTD Price Performance: 15.45%
Average Trading Volume: 362,025
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $80.33M
See more insights into ICCM stock on TipRanks’ Stock Analysis page.